Pharmacological inhibition of SF3B1 by pladienolide B reduces tumor growth in cervical cancer, hepatocellular cancer, glioblastoma, chronic lymphocytic leukemia, and endometrial cancer [14–18]. Here, SF3B1 is linked to endometrial cancer.